drugset / Trial / NCT01156025

Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis

NCT01156025

Phase 2 Completed 16 enrolled Laboratoires Thea
RandomizedParallel-groupDouble-blindTreatment

Summary

The study objective is to evaluate the efficacy and the safety of GV 550 in comparison to placebo in patients with acute adenoviral keratoconjuncivitis.

Timeline

Start
2009-03
Primary completion
2010-02
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganciclovir Small molecule 1.5 unknown Other
Background Hyabak Unknown Other